Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023

SELL
$40.65 - $59.54 $5,243 - $7,680
-129 Reduced 2.55%
4,925 $231,000
Q1 2023

Apr 24, 2023

SELL
$37.27 - $46.57 $7,193 - $8,988
-193 Reduced 3.68%
5,054 $212,000
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $5,441 - $7,370
-169 Reduced 3.12%
5,247 $200,000
Q3 2022

Oct 07, 2022

BUY
$32.28 - $43.27 $174,828 - $234,350
5,416 New
5,416 $212,000
Q2 2022

Aug 10, 2022

SELL
$27.52 - $37.99 $1.35 Million - $1.87 Million
-49,146 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $33,781 - $50,281
-1,100 Reduced 2.19%
49,146 $1.63 Million
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $48,178 - $61,243
1,300 Added 2.66%
50,246 $2.14 Million
Q3 2021

Nov 08, 2021

BUY
$40.26 - $57.37 $378,444 - $539,278
9,400 Added 23.77%
48,946 $2.17 Million
Q2 2021

Aug 11, 2021

BUY
$54.88 - $79.29 $900,032 - $1.3 Million
16,400 Added 70.85%
39,546 $2.25 Million
Q1 2021

May 14, 2021

BUY
$70.65 - $96.76 $1.03 Million - $1.41 Million
14,573 Added 169.99%
23,146 $1.73 Million
Q4 2019

Feb 13, 2020

BUY
$60.18 - $154.77 $481 - $1,238
8 Added 0.09%
8,573 $619,000
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $9,960 - $13,487
71 Added 0.84%
8,565 $1.2 Million
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $315,226 - $365,630
1,997 Added 30.74%
8,494 $1.56 Million
Q1 2019

May 15, 2019

BUY
$89.33 - $163.65 $333,558 - $611,069
3,734 Added 135.14%
6,497 $1.03 Million
Q4 2018

Feb 06, 2019

SELL
$81.94 - $139.71 $1.18 Million - $2.01 Million
-14,412 Reduced 83.91%
2,763 $265,000
Q3 2018

Nov 15, 2018

BUY
$138.11 - $169.04 $205,231 - $251,193
1,486 Added 9.47%
17,175 $2.43 Million
Q2 2018

Aug 13, 2018

BUY
$140.36 - $175.76 $1.91 Million - $2.39 Million
13,576 Added 642.5%
15,689 $2.46 Million
Q1 2018

May 14, 2018

BUY
$152.15 - $192.33 $321,492 - $406,393
2,113 New
2,113 $340,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.